Ausgewählte Studien

ORIGINAL ARTICLE Line-field confocal optical coherence tomography: new insights for psoriasis treatment monitoring C. Orsini Dermatology Unit, …Den ganzen Artikel lesen

Rachel Sommer, Corresponding Author Rachel Sommer [email protected] Institute for Health Services Research in Dermatology and Nursing (IVDP), University …Den ganzen Artikel lesen

Dermatologie (Heidelb). 2023 Oct 12. doi: 10.1007/s00105-023-05235-1. Online ahead of print. NO ABSTRACT PMID:37823915 | DOI:10.1007/s00105-023-05235-1 Den ganzen Artikel lesen

SummaryBackground and ObjectivesPsoriatic arthritis (PsA) warrants early diagnosis and treatment for optimal results. This study aimed to elucidate …Den ganzen Artikel lesen

SummaryBackgroundVisible blue light (wavelength 400–495 nm) is a promising new treatment option for both psoriasis and atopic dermatitis (AD). Whilst …Den ganzen Artikel lesen

Dermatologie (Heidelb). 2023 Oct 11. doi: 10.1007/s00105-023-05234-2. Online ahead of print. ABSTRACT INTRODUCTION: A number of new, highly effective biologic drugs for psoriasis have been approved over the past few decades, which raises the question whether psoriasis is still a disease that requires inpatient treatment. METHODS: We conducted a retrospective analysis of inpatient data between 2010 and 2019 (the last 10 years prior to the coronavirus disease 2019 [COVID-19] pandemic) from three G

To the Editor: Psoriasis affects nails in approximately 15% to 50% of patients, whereas isolated involvement is observed in 5% to 10% of …Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2023 Nov;21(11):1351-1357. doi: 10.1111/ddg.15191. Epub 2023 Oct 9. ABSTRACT BACKGROUND AND OBJECTIVES: Psoriatic arthritis (PsA) warrants early diagnosis and treatment for optimal results. This study aimed to elucidate routine monitoring activities for PsA with concurrent psoriasis (PsO) by dermatologists to gather data on how conditions for optimal treatment are ensured. PATIENTS AND METHODS: This non-interventional, prospective, epidemiological, cross-sectional study (20

Katja Grossschaedl, Katja Grossschaedl Department of Dermatology, Medical University of Graz, Graz, Austria Search for more papers by this …Den ganzen Artikel lesen

Journal of the European Academy of Dermatology and Venereology Volume 37, Issue S7 p. 15-16 Open Access Matthias Augustin, Corresponding Author Matthias …Den ganzen Artikel lesen

The journey of patients with skin diseases through healthcare has been scarcely investigated. To analyse the journey of people with skin diseases in …Den ganzen Artikel lesen

Introduction: Deucravacitinib, a newly approved oral medication for the treatment of patients with moderate to severe plaque psoriasis, demonstrated …Den ganzen Artikel lesen

Skin Health Dis. 2023 Jun 28;3(5):e263. doi: 10.1002/ski2.263. eCollection 2023 Oct. ABSTRACT In the literature there is no consensus on the correlation between early systemic intervention and better treatment response in psoriasis. Here we present data on the impact of disease duration (<5 years, 5-<10 years, and ≥10 years) on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis from the reSURFACE 1 and reSURFACE 2 phase 3 trials and the TRIBUTE phas

Eur J Immunol. 2023 Oct 6:e2350633. doi: 10.1002/eji.202350633. Online ahead of print. ABSTRACT In COVID-19, hyperinflammatory and dysregulated immune responses contribute to severity. Patients with pre-existing autoimmune conditions can therefore be at increased risk of severe COVID-19 and/or associated sequelae, yet SARS-CoV-2 infection in this group has been little studied. Here, we performed single-cell analysis of peripheral blood mononuclear cells from patients with three major autoimmune

Dermatol Ther (Heidelb). 2023 Oct;13(10):2153-2169. doi: 10.1007/s13555-023-01003-0. Epub 2023 Sep 23. ABSTRACT Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line choice in topical psoriasis treatment. A CAL/BDP cream based on polyaphron dispersion (PAD) Technology has emerged as a novel formulation for a more

Original Paper Background: Digital media are easily accessible without time restrictions and are widely used for health- or disease-related purposes. …Den ganzen Artikel lesen

ORIGINAL ARTICLE Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? – Insights from an international population-based study …Den ganzen Artikel lesen

Appl Health Econ Health Policy. 2023 May 30. doi: 10.1007/s40258-023-00815-7. Online ahead of print. ABSTRACT OBJECTIVES: The German Pharmaceutical Market Restructuring Act (AMNOG, 2011) is a two-stage process to regulate the price of new pharmaceuticals in which price negotiations are conducted based on evidence-based medical benefit assessments using data from prior clinical trials. Although the act does not explicitly set a willingness-to-pay (WTP) threshold, the process itself implicitly est

J Eur Acad Dermatol Venereol. 2023 May 29. doi: 10.1111/jdv.19229. Online ahead of print. ABSTRACT BACKGROUND: Tildrakizumab (TIL) is an interleukin (IL)-23p19 inhibitor for the treatment of moderate-to-severe plaque psoriasis with long-term efficacy and safety demonstrated in phase III trials. Studies conducted in conditions closer to clinical practice are needed. OBJECTIVES: The TRIBUTE study (open-label, phase IV) assessed the efficacy and impact on Heath-Related Quality of Life (HRQoL) of TI

SummaryThe incidence of autoimmune diseases in industrialized countries is constantly increasing over past decades. These diseases lead to increased …Den ganzen Artikel lesen

• Cameron A.C. • Miller D.L. A practitioner’s guide to cluster-robust inference. Journal of human resources. 2015; 50: 317-372 Farzanfar D. • Dowlati Y. • French …Den ganzen Artikel lesen

Actas Dermosifiliogr. 2023 May 25:S0001-7310(23)00397-6. doi: 10.1016/j.ad.2023.05.016. Online ahead of print. ABSTRACT Managing moderate to severe psoriasis in older adults is complex due to factors characteristic of the later years of life, such as associated comorbidity, polypharmacy, and immunosenescence. This consensus statement discusses 17 recommendations for managing treatment for moderate to severe psoriasis in patients older than 65 years. The recommendations were proposed by a committ

Skornicki M, Prince P, Suruki R, Lee E, Louder A. Skornicki M, et al. Adv Ther. 2021 May;38(5):2458-2471. doi: 10.1007/s12325-021-01698-7. Epub 2021 …Den ganzen Artikel lesen

EudraCT Number: 2020-004081-19 Sponsor Protocol Number: 20-01/BetaSal-S Start Date*: 2021-12-22 Sponsor Name:Dermapharm AG Full Title: Double-blind, …Den ganzen Artikel lesen

MMW Fortschr Med. 2023 May;165(10):10. doi: 10.1007/s15006-023-2681-x. NO ABSTRACT PMID:37202665 | DOI:10.1007/s15006-023-2681-x Den ganzen Artikel lesen